Skip to content
OpenCapital
Collapse sidebar
Watchlist
Screener
Filings
Earnings
Charts
Collapse sidebar
Screener
Stocks
Royalty Pharma
Business Segments
Products & Services
Research and development commitment
Research and development commitment
Royalty Pharma
·
Products & Services
·
3 segments
Breakdown
Segments
Phase 2b, TEV-408
View metric
Phase 3, TEV-408
View metric
TEV-408
View metric
Watchlist
Screener
Filings
Earnings
Charts
Quarterly
Annual
TTM
Segment
Q1 '26
Phase 3, TEV-408
$425M
Phase 2b, TEV-408
$75M
Total
$75M
